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ABstRACt
Objective: To investigate the percentage of ideal patients who 
would be eligible for hip-resurfacing surgery at a reference ser-
vice for hip arthroplasty. Methods: Out of all the cases of hip 
arthroplasty operated at Hospital do Servidor Público Estadual 
de São Paulo (HSPE) between January 2009 and December 
2010, we assessed a total of 592 procedures that would fit 
the criteria for indication for resurfacing arthroplasty, after 
clinical and radiological evaluation according to the criteria 
established by the Food and Drug Administration (FDA) and 
INtRODUCtION
In the 1950s, John Charnley apud Seyler et al(1) 
introduced what can be considered to be the first 
concept of resurfacing arthroplasty, using implants 
made from Teflon®. The idea was abandoned because 
of disastrous results early on. At the end of the 1980s, 
another attempt at resurfacing was made by Wagner, 
using a metal-to-metal contact surface. Resurfacing 
was then only reintroduced at the end of the 1990s, 
with advances in tribology. Nonetheless, there is still 
much discussion in the medical literature regarding 
its real indication. On the other hand, it is known that 
the clinical results are extremely dependent on good 
patient selection(2-7) and on the details of the surgical 
technique(4,8-11). According to the criteria currently 
used, it is seen that only a small percentage of the 
patients would be candidates for this technique. This 
is a matter for concern, given the long learning curve 
required for this procedure to be performed. According 
to Nunley et al(12), the learning curve for avoiding 
early postoperative complications involves at least 
25 procedures, and to achieve good postoperative 
radiographic parameters, 75 to 100 procedures. In 
this light, we conducted the present study with the aim 
of ascertaining the eligibility of patients who could 
undergo hip-resurfacing arthroplasty (HRA) in our 
setting and, through this, to investigate the viability 
of capacitating hip surgeons to perform this technique.
OBJECtIVE
The aim of this study was to quantify the num-
ber of patients who might have been eligible for the 
technique of HRA at the Orthopedics and Trauma-
tology Clinic of the State Public Servants’ Hospital 
(Hospital do Servidor Público Estadual, HSPE) in the 
years 2009 and 2010, out of a total of 592 hips that 
underwent hip arthroplasty.
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by Seyler et al. Results: Among the total number of hip repla-
cement arthroplasty cases, 5.74% of the patients were eligible. 
Among the patients who underwent primary arthroplasty, we 
found that 8.23% presented ideal conditions for this procedure. 
Conclusion: The study demonstrated that this type of surgery 
still has a limited role among hip surgery methods. 
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MAtERIAL AND MEtHOD
A survey of all the orthopedic surgical procedu-
res performed between January 2009 and December 
2010 at HSPE was conducted. Among these, there 
were 592 hip arthroplasty procedures, of which 41% 
were on male patients and 59% on female patients. 
The patients’ mean age was 60.3 years, with a range 
from 27 to 98 years. Through our database, we were 
able to initially screen the patients to exclude those 
for whom HRA would not be applicable because of 
the presence of femoral neck fractures, and also tho-
se who underwent hip revision arthroplasty, totaling 
139 (23%) and 40 (7%) of the patients respectively 
(Figure 1).
The second step of our investigation consisted 
of a clinical evaluation, by means of reviewing the 
medical files, and a radiographic evaluation, through 
assessing radiographic examinations in anteroposte-
rior and lateral views on all the hips that had been 
operated using the standard technique. These exami-
nations were all performed within the last preopera-
tive month. In reviewing the medical files, we looked 
for data on previous pathological conditions such as 
neuromuscular and vascular diseases, diagnoses of 
osteoporosis or family histories of this, kidney failure 
(also assessed through preoperative examinations), 
obesity, acquired immunodeficiency syndrome, chro-
nic use of corticoids or other immunosuppressants, or 
hip diseases during childhood. The assessments on the 
radiographic examinations consisted of quantifying 
the extent to which the femoral head was compromi-
sed in cases of osteonecrosis, the presence of cysts 
and their sizes, the presence of osteoporosis, asses-
sed according to parameters defined by Singh et al(13) 
(such that cases classified as grade 3 or lower were 
classified as osteoporosis), dysplastic abnormalities 
of the hip, signs of femoroacetabular impact and pre-
sence of Legg-Calvé-Perthes disease. Access to the 
radiographs was possible through images retrieved 
from the digitized system for imaging examinations 
at HSPE. The assessments on the medical files and 
radiographic examinations were done in conjunction 
by two residents of orthopedics and traumatology at 
HSPE, one orthopedist who was a specialist in hip 
surgery and two experienced hip surgeons.
In this second stage, among the 413 patients who 
remained, we applied the criteria for contraindica-
tion of HRA of the United States Food and Drug 
Administration (FDA)(14,15). These criteria involved 
the following clinical parameters: active infection 
in the organism; skeletal immaturity; clinical situa-
tions presented by patients that might compromise 
the stability of the implant (muscle atrophy, neu-
romuscular diseases and vascular insufficiency); 
women of fertile age (limit of 45 years); kidney fai-
lure; severe obesity (body mass index greater than
40 kg/m2); patients with immunological depression 
(due to acquired immunodeficiency syndrome, use 
of corticoids at immunosuppressant doses or use of 
other immunosuppressant agents); and known sensiti-
vity to metal. The radiographic parameters included: 
osteoporosis; osteonecrosis affecting more than 50% 
of the femoral head; multiple cysts or cysts larger 
than 1 cm; questionable bone stock, defined as bone 
mineral density lower than 0.65 g/cm2 or a T-score 
lower than –1 on bone densitometry(16) (Table 1). 
At this stage, 292 patients presented contraindica-
tions according to the FDA criteria. The main con-
traindications among females were osteoporosis (the 
most prevalent contraindication) (Figure 1), use of 
immunosuppressants (particularly in cases of rheu-
matoid arthritis) and fertile age. Among males, the 
main contraindications were cases of a compromised 
femoral head (more than 50% affected), with or wi-
thout associated multiple cysts larger than 1 cm; and 
osteoporosis. There were no cases relating to allergy 
to metal or cases of infection.
Figure 1 – (A) compromising of the femoral head greater than 50%; (B) femoral neck fracture; (C) multiple cysts.
A B C
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After the exclusions made in the second stage, 121 
patients remained. Through the data already gathered 
and from our database of radiographic examinations, 
we placed each patient individually in the algorithm 
proposed by Seyler et al(1) (Figure 2). This algorithm 
was created with the objective of allowing both novice 
and experienced surgeons to reduce the complications 
associated with the procedure and improve the clinical 
results, i.e. to select ideal patients. The majority of 
the contraindications contained in the algorithm are 
similar to those of the FDA, although Seyler empha-
sizes that it would be more prudent for surgery on the 
following types of cases to be avoided by inexperien-
ced surgeons: patients at the age extremities (< 35 
and > 65 years for men; and < 35 and > 55 years for 
women) and cases of inflammatory arthritis, dysplasia, 
femoroacetabular impact, bone metabolism diseases, 
compromised head (> 35% in relation to Perthes) or 
osteonecrosis of the femoral head.
At the end of the study, we were able to set up an 
organogram providing an explanation of the assessment 
stages, as shown in Figure 3. In the first stage, it shows 
the exclusion of patients who underwent revision 
arthroplasty and those with femoral neck fractures; 
in the second stage, the exclusion of patients who 
did not meet the FDA criteria; and in the third stage, 
the exclusion of patients who, despite being eligible 
according to the FDA criteria, were not eligible 
according to the Seyler criteria. 
REsULts
Only 5.74% of the total number of arthroplas-
ties performed at HSPE would have been ideal can-
didates for resurfacing between January 2009 and 
December 2010. From assessing only the cases of 
primary hip arthroplasty, only 8.23% out of the total 
of 413 procedures would have been candidates for 
HRA (Figures 4 and 5).
table 1 – Contraindications against hip resurfacing arthroplasty according 
to the FDA.
Infection of the organism 
Skeletal immaturity
Clinical situation presented by the patient that might compromise 
implant stability
• Muscle atrophy
• Neuromuscular diseases
• Vascular insufficiency
Inadequate bone quality for supporting the implant
• Severe osteopenia or osteoporosis 
• Family history of severe osteoporosis or severe osteopenia
• Osteonecrosis affecting > 50% of the femoral head (independent 
of Ficat stage)
• Multiple cysts on the femoral head (> 1 cm) 
• Questionable bone stock (surgeon should order a bone 
densitometry scan to assess whether the bone mass is inadequate)
Women of fertile age
Kidney failure (renal function tests are required, including the 
glomerular filtration rate for creatinine and blood urea-nitrogen)
Severe obesity
Suppression of the immunological system due to diseases such 
as acquired immunodeficiency syndrome (AIDS) or high doses of 
corticosteroids and/or immunosuppressants 
Known sensitivity to metals
Figure 2 – Seyler algorithm.
Patients who are candidates for resurfacing 
arthroplasty
Sex
men Women
Age Age
< 35 or > 65 
years of age
35 to 65 years
of age
> 35 or < 55 
years of age
> 35 years
of age
> 55 years
of age
Care for 
inexperienced 
surgeons
Etiology
Care for 
inexperienced 
surgeons
Adequate 
bone stock Bone densitometry
Metabolic 
diseases
Osteonecrosis
Perthes disease
Osteonecrosis
Post-traumatic arthritis
Inflammatory arthritis
Dysplasia/Impact
Osteoporosis
Surgery no 
recommended
> 35%
of head
Yes No ideal candidate Care for inexperienced 
surgeons
Surgery no 
recommended
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DIsCUssION
Resurfacing arthroplasty emerged over the last few 
years. Alongside this growth, the numbers of publi-
shed papers and controversies also grew. Despite the 
published data, it remains unclear which candidates 
are best for this technique and what the absolute and 
relative contraindications are(1).
The demand for HRA has been increasing recently, 
both from patients and from hip surgeons. Before May 
2006, when the FDA approved the first resurfacing 
method, using metal-to-metal surfaces, only a small 
group of surgeons in the United States was authori-
zed to perform resurfacing(17-20). The main restrictions 
laid down by the FDA relate to the complications 
observed in the clinical studies that were conducted to 
gain approval for this type of implant, especially the 
large number of peri-implant fractures and excessive 
increases in metal levels in the blood(12). Recently, the 
FDA(14,15) determined that all manufacturers of pros-
theses with metal-to-metal contact surfaces should 
conduct studies on patients to ascertain whether they 
had high levels of metal ions in their organisms. It 
also communicated through its website that patients 
with certain resurfacing implants, from certain ma-
nufactures would be invited to undergo blood tests to 
assay the chromium and cobalt ion levels, and to un-
dergo imaging examinations (magnetic resonance or 
ultrasound) to evaluate any occurrences of soft-tissue 
retraction, fluid accumulation or tumor formation. If 
present, revision surgery should be considered. 
In relation to sex, the published studies are also 
contradictory regarding indications for this type of 
arthroplasty in women. Some studies have shown 
that femoral neck fractures occur more frequently in 
female patients who undergo HRA than among male 
patients(20,21), and that females present higher revision 
rates(22). Other studies, such as by Amstutz et al(23), did 
not show any significant difference in the frequency 
of complications found in women, in relation to men. 
There is also concern regarding the increased se-
rum levels of metal ions caused by metal-to-metal 
prostheses, which are the only type of HRA prosthesis 
authorized by the FDA, including in relation to wo-
men of fertile age. There is clear evidence to sustain 
the notion that metal ion levels increase in patients 
who receive metal-to-metal prostheses(24-27). Although 
there have already been studies suggesting that this 
does not have any consequences for the fetus and 
Figure 3 – Patients assessed through the three stages of the study and final candidates 
for resurfacing.
Figure 4 – Patients eligible for HRA out of the total number of patients who underwent 
replacement arthroplasty at HSPE between january 2009 and December 2010.
Figure 5 – Percentage indication of HRA out of the primary hip arthroplasties performed.
592 
patients
40 patients 
with revision
413
patients
139 patients 
with femoral 
neck fractures
292 patients 
excluded 
according to FDA 
criteria
121 patients
87 patients 
excluded 
according to 
Seyler criteria
34 patients 
deemed to be 
candidates for 
resurfacing 
arthroplasty
Total number of 
patients
First stage 
(exclusion of 
cases of fracture 
and revision 
arthroplasty)
Second stage
Third stage (Seyler)
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Patients eligible for HRA out of the 
total number of patients
Non-eligible patients
Eligible patients
5.74%
93.26%
Patients who underwent primary 
hip arthroplasty
Candidates for resur-
facing arthroplasty
Patients who 
underwent primary 
arthroplasty without 
an indication for
resurfacing91.77%
8.23%
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that the placenta may function as a selective barrier 
against these ions(24,28), there is still a lack of studies 
proving this. Therefore, this possibility should still be 
taken into account in the exclusion criteria for selec-
ting patients to be candidates for HRA.
Comparisons in the literature between resurfacing 
and conventional total arthroplasty, in similar groups 
of patients, with procedures performed by experiences 
and capacitated surgeons, show that over the short 
term, there are no great differences between the two 
procedures. Sandiford et al(29) compared groups of 
young and active patients who underwent uncemen-
ted total hip arthroplasty or resurfacing arthroplasty 
in order to deal with their complaints and functional 
demands, with a short clinical follow-up. These au-
thors concluded that the patients did not present any 
significant difference in relation to either postoperati-
ve satisfaction or functional demand. Fowble et al(30) 
also compared the two techniques and concluded that 
there were no significant differences in the clinical 
results. However, conventional total hip arthroplasty 
presented shorter duration of surgery, with a mean 
of 148 minutes, versus 174 minutes, and complete 
pain relief in 80% of the patients, while resurfacing 
presented 48%. On the other hand, the patients who 
underwent resurfacing presented less bleeding during 
the operation and immediately afterwards, via va-
cuum drainage. Marker et al(31) conducted a review of 
the literature and compared studies on total hip arthro-
plasty and resurfacing with regard to basic science, 
radiographic criteria and clinical issues. These authors 
also concluded that in the literature, no advantages 
were shown for one procedure in relation to the other. 
With regard to radiographic characteristics, such as 
the positions of the components and correction of 
the offset, conventional arthroplasty presents a rela-
tive advantage. In addition, the length of follow-up 
in studies on resurfacing was shorter than in studies 
on total hip arthroplasty.
Regarding the patients’ ages, there is a consensus 
in the literature in relation to the concept that the older 
the patient is, the greater the risk of early revision 
following resurfacing arthroscopy becomes. Accor-
ding to data from the National Joint Replacement 
Registry of the Australian Orthopaedic Association, 
in its 2008 Annual Report(21), the revision rates over 
the first five postoperative years were 3.1% among 
patients under the age of 55 years, 4.1% between 55 
and 64 years, 5% between 65 and 74 years and 9.9% 
among patients over the age of 75 years. Today, many 
authors contraindicate HRA in male patients over the 
age of 65 years(32-34).
From a review of the literature and clinical stu-
dies, Seyler et al(1) proposed an algorithm to facilitate 
indications for resurfacing and decisions on patient 
eligibility. Application of this algorithm allows stan-
dardization of patient selection, both for novice and 
for experienced surgeons, and has the aim of redu-
cing the complications associated with this procedure. 
Selecting a technique that is associated with better 
patient indication is reflected in better clinical results. 
In the survey conducted at HSPE, this algorithm was 
used on the patients who underwent hip arthroplasty 
in 2009 and 2010, and the criteria for absolute con-
traindication according to the FDA were also taken 
into consideration. Seyler et al(1) recommended that 
surgeons should assess the characteristics of the ace-
tabulum and femoral neck, which may influence the 
technical aspects of the resurfacing process and con-
sequently the survival of the implant.
Because resurfacing is still a little-used procedure 
in Brazil, few clinics are capacitated to perform it. 
In a study with level II evidence, Nunley et al(7) de-
termined the learning curve associated with resurfa-
cing. They compared the rate of early complications 
from resurfacing procedures among the first 650 hips 
operated by five experienced surgeons and a national 
database. They concluded that for experienced hip 
surgeons, the learning curve for avoiding early clini-
cal complications was approximately 25 cases. Ho-
wever, even so, they presented unsatisfactory implant 
positioning and radiographic findings. The learning 
curve for experienced surgeons to achieve the desired 
positioning of components, assessed radiographically, 
was much longer: 75 to 100 cases or more. 
In the survey conducted at HSPE, even though 
the volume of surgical cases was relatively large in 
relation to other Brazilian clinics, the number of cases 
eligible for resurfacing during the years 2009 and 
2010 was 34 patients, i.e. approximately two years of 
training for an experienced surgeon. In another study 
conducted by O’Neill et al(35), it was found that the 
complication rate from the initial cases of resurfa-
cing arthroplasty was not unacceptably high in any of 
the academic centers in Canada in 2007. It is impor-
tant to emphasize that in their study, all the surgeons
Rev Bras Ortop. 2012;47(4):460-6
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involved were hip specialists and were considered to 
be experienced, with large volumes of surgical ca-
ses. As with any new technique, patient selection is 
fundamentally important, and the indications need to 
be precise. Although studies on a single experienced 
surgeon with a large volume of surgical cases have 
shown results comparable with those from total hip 
arthroplasty, four recent multicenter studies reported 
failure rates from resurfacing of 6 to 7.4%, over a 
short follow-up period(36-39). Thus, the learning curve 
associated with resurfacing might be considered to be 
excessively steep to justify offering this as a safe and 
effective means of treating hip arthrosis, especially 
if the surgeon is inexperienced. However, this argu-
ment has left some unanswered questions regarding 
the role of resurfacing in treating hip arthrosis. Hence, 
it is important to analyze the number of cases with 
an indication for this treatment and the learning cur-
ve for this procedure in a group of surgeons without 
previous training, but with significant experience of 
hip arthroplasty. In this case, at the Hip Surgery Cli-
nic of HSPE, among the patients selected after using 
the algorithm, the learning curve and particularly its 
length would be relatively long.
Regarding the rate of use of the HRA technique, it 
accounted for around 8% of the primary hip arthro-
plasty procedures performed in Australia in 2007, and 
it has been found to range between 6 and 9% in Eu-
rope, i.e. similar to the results obtained in the present 
study. The Australian registry indicates that there is 
greater risk of early revision after resurfacing, during 
the first six to 12 months after the operation(12). Howe-
ver, after the first postoperative year, the revision rates 
do not differ between resurfacing and conventional ar-
throplasty when the patients are adequately selected. 
These high revision rates during the first 12 months 
are considered to be related to the surgical technique 
and to the precision of component positioning(12). 
CONCLUsION
The surgeon’s experience and precise selection of 
patients continue to be key factors for success in this 
procedure. The importance of selecting the patients 
must not be underestimated, especially for surgeons 
who are at the start of the learning curve. The algo-
rithm used here can be used to standardize patient 
selection and obtain better results. In our study, this 
type of surgery was shown to still have a limited role 
among hip surgery methods.
Rev Bras Ortop. 2012;47(4):460-6
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